Retinalgenix Technologies Stock Analysis
| RTGN Stock | USD 3.20 0.00 0.00% |
RetinalGenix Technologies' financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. RetinalGenix Technologies' financial risk is the risk to RetinalGenix Technologies stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Given that RetinalGenix Technologies' debt-to-equity ratio measures a OTC Stock's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which RetinalGenix Technologies is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of RetinalGenix Technologies to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, RetinalGenix Technologies is said to be less leveraged. If creditors hold a majority of RetinalGenix Technologies' assets, the OTC Stock is said to be highly leveraged.
RetinalGenix Technologies is fairly valued with Real Value of 3.2 and Hype Value of 3.2. The main objective of RetinalGenix Technologies otc analysis is to determine its intrinsic value, which is an estimate of what RetinalGenix Technologies is worth, separate from its market price. There are two main types of RetinalGenix Technologies' stock analysis: fundamental analysis and technical analysis.
The RetinalGenix Technologies otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
RetinalGenix |
RetinalGenix OTC Stock Analysis Notes
About 66.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.05. RetinalGenix Technologies had not issued any dividends in recent years. RetinalGeniX Technologies, Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC. Retinalgenix Technologies operates under Medical Devices classification in the United States and is traded on OTC Exchange.The quote for RetinalGenix Technologies is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about RetinalGenix Technologies contact Jerry Katzman at 415 578 9583 or learn more at https://retinalgenix.com.RetinalGenix Technologies Investment Alerts
| RetinalGenix Technologies generated a negative expected return over the last 90 days | |
| Net Loss for the year was (2.18 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| RetinalGenix Technologies currently holds about 27 in cash with (1.17 M) of positive cash flow from operations. | |
| Roughly 66.0% of the company outstanding shares are owned by corporate insiders |
RetinalGenix Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 162.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate RetinalGenix Technologies's market, we take the total number of its shares issued and multiply it by RetinalGenix Technologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of RetinalGenix Technologies, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze and collect data for zero technical drivers for RetinalGenix Technologies, which can be compared to its competitors.RetinalGenix Technologies Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in RetinalGenix Technologies price series with the more recent values given greater weights.
RetinalGenix Technologies Outstanding Bonds
RetinalGenix Technologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. RetinalGenix Technologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most RetinalGenix bonds can be classified according to their maturity, which is the date when RetinalGenix Technologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| US76131VAB99 Corp BondUS76131VAB99 | View |
RetinalGenix Technologies Debt to Cash Allocation
RetinalGenix Technologies currently holds 114.69 K in liabilities. Debt can assist RetinalGenix Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, RetinalGenix Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RetinalGenix Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RetinalGenix to invest in growth at high rates of return. When we think about RetinalGenix Technologies' use of debt, we should always consider it together with cash and equity.RetinalGenix Technologies Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the RetinalGenix Technologies' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of RetinalGenix Technologies, which in turn will lower the firm's financial flexibility.RetinalGenix Technologies Corporate Bonds Issued
About RetinalGenix OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how RetinalGenix Technologies prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling RetinalGenix shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as RetinalGenix Technologies. By using and applying RetinalGenix OTC Stock analysis, traders can create a robust methodology for identifying RetinalGenix entry and exit points for their positions.
RetinalGeniX Technologies, Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC. Retinalgenix Technologies operates under Medical Devices classification in the United States and is traded on OTC Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding RetinalGenix Technologies to your portfolios without increasing risk or reducing expected return.Did you try this?
Run ETF Categories Now
ETF CategoriesList of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
| All Next | Launch Module |
Other Information on Investing in RetinalGenix OTC Stock
RetinalGenix Technologies financial ratios help investors to determine whether RetinalGenix OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in RetinalGenix with respect to the benefits of owning RetinalGenix Technologies security.